2 октябрь 2023
Sofia, Bulgaria, 2 October 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that in pursuance of a decision of the General meeting of Holders of Warrants (GMHW) held on 02.06.2023 and decision of the Board of Directors of SOPHARMA AD from a meeting held on 05.06.2023 and based on art. 195 and art. 196 of the Commercial Law (CL), art. 113, para. 2, item 2 of Law on public offering of securities (LPOS) and art. 25 of the Articles of incorporation of the company a procedure for capital increase was launched for issuing up to 44 925 943 ordinary registered dematerialized freely transferable shares with a nominal value of BGN 1 each and issue value of BGN 4.13 for one share, under the condition that the shares of the increase are subscribed by the holders of warrants of issue with ISIN BG9200001212, in accordance with the terms and conditions described in the Prospectus for Public Offering of Warrants, confirmed by a Decision of the Financial Supervision Commission (FSC) No 804-E / 04.11.2021.
The deadline for exercising warrants set by the Board of Directors in accordance with the requirements of the LPOS and the Prospectus for Public Offering of Warrants, confirmed by FCS Decision No 804-E / 04.11.2021 started on 07.09.2023 and ended on 29.09.2023. For this period, a total of 260 applications for subscription of the shares from the increase through the exercise of warrants were submitted by 249 persons, including 23 legal entities and 226 individuals. A total of 37 792 679 (thirty-seven million seven hundred and ninety-two six hundred and seventy-nine) warrants was exercised and respectively 37,792,679 (thirty-seven million seven hundred and ninety-two leva six hundred and seventy-nine) shares from the capital increase were subscribed through investment intermediary “Sofia International Securities” AD.
The persons who have the right to participate in the capital increase of SOPHARMA AD by exercising the warrants were those who acquired warrants 5 working days after the later date between the date of disclosure of this notice under Art. 89t, para. 2 from LPOS on the website of X3news.com Information Agency, on the website of “SOPHARMA” AD and the investment mediator selected to serve the capital increase at the latest. The issue price of the subscribed shares amounts to a total of BGN 156 083 764.27 (one hundred and fifty-six million eighty-three thousand seven hundred and sixty-four leva and 27 stotinki).
During the period for subscription, including during the exercise of the warrants and the subscription of the shares, the Company has encountered no difficulties, disputes or similar issues. The subscription is considered successful.
A procedure for registration of the capital increase in the Commercial Register, in the registers of the Central Depository AD, the Financial Supervision Commission, etc. is forthcoming.